Brief: Rein Therapeutics Paused Its Phase 2 Renew Trial Of Lti-03 In The U.S.
12/06/2025 22:06
June 12 (Reuters) - Rein Therapeutics Inc RNTX.O: REIN THERAPEUTICS : PAUSED ENROLLMENT AND PATIENT DOSING AT ITS CLINICAL TRIAL SITES IN UNITED STATES (U.S.) FOR ITS PHASE 2 RENEW TRIAL OF LTI-03 REIN THERAPEUTICS INC - RENEW TRIAL CONTINUES IN AUSTRALIA, UK, AND EUROPE - SEC FILING REIN THERAPEUTICS INC - NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED FOR LTI-03 - SEC FILING Source text: [ID:n0001193125-25-139950] Further company coverage: RNTX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering